supernu report dilut ep revenu compar street
estim respect given strong trokendi xr
believ absenc clear upward revis sale guidanc concern
interpret signal manag caution regard evolv
competit dynam migrain prophylaxi space given avail
aimovig eventu anti-cgrp monoclon antibodi given backdrop
realiti trokendi xr lose exclus cautiou stanc adhd
pipelin name commerci risk surround view
risk/reward profil attract ebitda around
reiter neutral rate lower pt
solid quarter trokendi xr beyond would worri
trokendi xr sale grew versu sale grew
sequenti versu total prescript rx trokendi xr grew
versu grew versu per iqvia thu far rx
show growth rate versu respect
said new rx show declin thu far versu new
rx grew versu continu believ visibl
continu aggress volum growth product murki given avail
anti-cgrp agent reason price point aimovig list price lower
trokendi xr recent check migrain specialist reinforc view
refer note detail survey
latest oxtellar xr sale oxtellar xr versu sale
versu sale total rx show quarter-
to-dat growth rate versu respect
expect fda action file epilepsi monotherapi year-end
take cautiou view manag note see data
one two phase studi pediatr adhd patient recal
product known viloxazin norepinephrin ne reuptak inhibitor new
chemic entiti regard competit landscap non-stimul front
would keep close eye sunovion dasotralin ne-dopamin reuptak inhibitor
review fda agenc accept sunovion nda last novemb
given strattera avail gener gener account
strattera rx given realiti restrict payer environ broadli
speak along exist anoth brand non-stimul launch ahead
would take cautiou view peak sale potenti
nowher near strattera peak around per iqvia
ep disc
debt total capit
commerci risk epilepsi product clinic risk adhd pipelin
supernu focus treatment disord
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
actual versu pjc consensu estim
consensu estim
compani report factset pjc estim
compani report pjc estim
includ approxim million licens non-cash royalti revenu
page
million except per shareactualpjc estimatesrevenuetrokendi xr mr xr mr consensu consensu outstand except per guidanceestimatestot product
consensu
compani report factset pjc estim
page
million except per sharecurrentpriorcurrentpriorcurrentpriorrevenuestrokendi xr mr xr mr gener oper incom expens tax provis outstand supernu quarterli annual incom statement
million except ep
sale
sell gener administr
amort intang
incom loss tax
expens product sale
sell gener administr
royalti sale partner product includ payment unit relat fda approv orenitram receipt payment relat royalti stream orenitram
proprietari piper jaffray co august
current disclosur inform compani found http //www piperjaffray com/researchdisclosur
